Clinical Effectiveness and Outcomes of Azithromycin versus Doxycycline Containing Regimen in Inpatients with Community Acquired Pneumonia: A Retrospective Cohort Study

被引:0
|
作者
Babonji, Alaa S. [1 ]
Alshehri, Sara J. [2 ]
Alturaiki, Abdulrahman M. [3 ]
机构
[1] Minist Natl Guard Hlth Affairs, King Abdulaziz Univ Hosp Jeddah, King Abdulaziz Med City, Jeddah, Saudi Arabia
[2] Minist Natl Guard Hlth Affairs, King Abdulaziz Med City, Riyadh, Saudi Arabia
[3] Minist Natl Guard Hlth Affairs, Internal Med Clin Pharm, King Abdulaziz Med City, Riyadh, Saudi Arabia
关键词
HOSPITALIZED-PATIENTS; ADULTS; EPIDEMIOLOGY; MANAGEMENT; DIAGNOSIS; STABILITY; THERAPY;
D O I
10.1155/2023/8861376
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background. Community acquired pneumonia (CAP) is a common serious infection that is usually treated with a macrolide with a beta-lactam while doxycycline is considered an alternative due to limited evidence. Hence, we aimed to evaluate azithromycin versus doxycycline containing regimen in achieving clinical stability for inpatients with CAP. Materials and Methods. a retrospective cohort of inpatients with CAP receiving either azithromycin or doxycycline combined with a beta-lactam. The primary endpoint was the percentage of patients who achieved clinical stability within 3 days, while secondary endpoints were the average days required to achieve clinical stability. Results. A total of 447 were included of which 379 received azithromycin while 68 received doxycycline containing regimen.The average age of the study population was 65.4 +/- 21.1, of which 49% were females. Ceftriaxone was the most prescribed beta-lactam. Majority of this cohort had a length of hospital stay of 5 days or less. Total percentage of patients who achieved clinical stability within 3 days were 257 (57.5%), of which 222 (58.6%) were in azithromycin group versus 35 (51.5%) in doxycycline containing regimen group; p = 0.275. While the average day required to achieve clinical stability in both groups was 3.8 +/- 3.2, in which 3.8 +/- 3.3 in azithromycin versus 3.9 +/- 2.7 in doxycycline containing regimen; (95% CI -0.98-0.68; p. 0.727) Conclusions. These findings support that doxycycline is comparable in efficacy to macrolides with a beta-lactam for inpatients with CAP as supported by current guideline recommendations.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Levofloxacin versus ceftriaxone and azithromycin for treating community-acquired pneumonia: a randomized clinical trial study
    Yadegarynia, Davood
    Tehrani, Shabnam
    Nejad, Fatemeh Maghsoudi
    Shojaeian, Fatemeh
    Keyvanfar, Amirreza
    [J]. IRANIAN JOURNAL OF MICROBIOLOGY, 2022, 14 (04) : 458 - 465
  • [2] β-Lactams plus doxycycline versus azithromycin for treatment of severe community-acquired pneumonia in critically ill patients
    Kinney, Alexandra Greco
    Scherrer, Nicole Kovacic
    Sarkar, Sauradeep
    Jain, Pranav
    Wen, Sijin
    Hadique, Sarah
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (12) : 2816 - 2823
  • [3] Impact of social deprivation on clinical outcomes of adults hospitalised with community-acquired pneumonia in England: a retrospective cohort study
    Lawrence, Hannah
    McKeever, Tricia M.
    Lim, Wei Shen
    [J]. BMJ OPEN RESPIRATORY RESEARCH, 2022, 9 (01)
  • [4] USE OF AZITHROMYCIN FOR COMMUNITY-ACQUIRED PNEUMONIA: A RETROSPECTIVE STUDY IN A TERTIARY AUSTRALIAN HOSPITAL
    Qian, Sue
    Siu, Johnny
    Hussein, Abbas El-Hajj
    Zheng, Yizhong
    [J]. CHEST, 2021, 160 (04) : 500A - 500A
  • [5] The impact of hyperglycemia on community-acquired pneumonia: A retrospective cohort study
    Jensen, Andreas Vestergaard
    Baunbaek-Knudsen, Gertrud
    Andersen, Stine Bang
    Petersen, Pelle Trier
    Benfield, Thomas
    Faurholt-Jepsen, Daniel
    Rohde, Gernot
    Ravn, Pernille
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [6] Clinical characteristics and outcomes of immunocompromised patients with severe community-acquired pneumonia: A single-center retrospective cohort study
    Wu, Xiaojing
    Sun, Ting
    Cai, Ying
    Zhai, Tianshu
    Liu, Yijie
    Gu, Sichao
    Zhou, Yun
    Zhan, Qingyuan
    [J]. FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [7] The Neutrophil/Lymphocyte Ratio and Outcomes in Hospitalized Patients with Community-Acquired Pneumonia: A Retrospective Cohort Study
    Tekin, Aysun
    Wireko, Felix W.
    Gajic, Ognjen
    Odeyemi, Yewande E.
    [J]. BIOMEDICINES, 2024, 12 (02)
  • [8] AZITHROMYCIN FOR TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY LEGIONELLA-PNEUMOPHILA - A RETROSPECTIVE STUDY
    KUZMAN, I
    SOLDO, I
    SCHONWALD, S
    CULIG, J
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1995, 27 (05) : 503 - 505
  • [9] Azithromycin: 3-day versus 5-day dosage regimen for community-acquired pneumonia in children
    Ficnar, B
    Huzjak, N
    Klinar, I
    Matrapazovski, M
    [J]. EXPANDING INDICATIONS FOR THE NEW MACROLIDES, AZALIDES, AND STREPTOGRAMINS, 1997, 21 : 629 - 633
  • [10] Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community acquired pneumonia in adults
    Sopena, N
    Martínez-Vazquez, C
    Rodriguez-Suárez, JR
    Segura, F
    Valencia, A
    Sabrià, M
    [J]. JOURNAL OF CHEMOTHERAPY, 2004, 16 (01) : 102 - 103